Ligand Pharmaceuticals
LGND
298 hedge funds and large institutions have $3.35B invested in Ligand Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 123 increasing their positions, 99 reducing their positions, and 31 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 99
16% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 31
2% more funds holding
Funds holding: 293 → 298 (+5)
0% less capital invested
Capital invested by funds: $3.35B → $3.35B (-$361K)
0.02% less ownership
Funds ownership: 187.54% → 187.52% (-0.02%)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
61% less call options, than puts
Call options by funds: $7.11M | Put options by funds: $18.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$22.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16M |
| 3 |
O
OppenheimerFunds
New York
|
+$14.9M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$12.9M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$61.9M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$18.5M |
| 3 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$16.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13.1M |
LGND Hedge Fund Activity: Q4 2017 in Review
298 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2017, worth a combined $3.35B — down 0.01% from $3.35B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LGND positions and 31 closed out — a net gain of 5 holders — while 123 added to existing stakes and 99 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $22.2M. The largest seller was Bank of America, cutting an estimated $61.9M.
- 298 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2017, up from 293 in Q3 2017.
- Funds reported $3.35B of Ligand Pharmaceuticals stock for Q4 2017, down 0.01% quarter-over-quarter.
- 36 funds opened new Ligand Pharmaceuticals positions in Q4 2017 and 31 closed out, a net change of +5 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2017 was Janus Henderson Group, an estimated $22.2M added.
- The largest Ligand Pharmaceuticals seller in Q4 2017 was Bank of America, an estimated $61.9M sold.
Based on aggregated 13F filings for Q4 2017.